Scarica l'app Stockscreener
0.6217
10.31%
-0.0584
Dopo l'orario di chiusura:
.60
-0.0217
-3.49%
Precedente Chiudi:
$0.6801
Aprire:
$0.7
Volume 24 ore:
153.49K
Relative Volume:
1.79
Capitalizzazione di mercato:
$12.36M
Reddito:
-
Utile/perdita netta:
$-26.56M
Rapporto P/E:
-0.9565
EPS:
-0.65
Flusso di cassa netto:
$-22.29M
1 W Prestazione:
-36.38%
1M Prestazione:
-21.80%
6M Prestazione:
-56.43%
1 anno Prestazione:
-71.64%
Intervallo 1D:
$0.5818
$0.7038
Intervallo di 1 settimana:
$0.5818
$1.1609
Portata 52W:
$0.48
$8.55
BiomX Inc Stock (PHGE) Company Profile
Nome
BiomX Inc
Settore
Industria
Telefono
972 7 23942377
Indirizzo
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Confronta PHGE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
0.6217 | 12.36M | 0 | -26.56M | -22.29M | -0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-15 | Iniziato | Ladenburg Thalmann | Buy |
BiomX Inc Borsa (PHGE) Ultime notizie
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World
Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World
HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World
BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World
BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World
BiomX regains NYSE compliance - Investing.com
BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards - The Manila Times
BiomX Regains NYSE American Listing Compliance After Meeting All Standards - StockTitan
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 12.2% – Should You Sell? - Defense World
BiomX (PHGE) 5-Day RSI : 13.43 (As of Nov. 20, 2024) - GuruFocus.com
BiomX Announces Third Quarter 2024 Financial Results and Clinical Program Updates - Defense World
Biomx stock plunges to 52-week low, hits $0.61 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.61 By Investing.com - Investing.com Canada
BiomX shares hold Buy rating from H.C. Wainwright on Q3 results - Investing.com Canada
BiomX Inc. (AMEX:PHGE) Q3 2024 Earnings Call Transcript - Insider Monkey
BiomX Inc (PHGE) Q3 2024 Earnings Call Highlights: Strong Net In - GuruFocus.com
BiomX Inc. Reports Q3 2024 Financial Turnaround - TipRanks
BiomX Inc (PHGE) Quarterly 10-Q Report - Quartzy
BiomX Inc (PHGE) Reports Q3 2024 Net Income of $9.6 Million Amid Increased R&D and Administrative Expenses - GuruFocus.com
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates - The Manila Times
BiomX Completes Trial Enrollment, Reports $9.6M Net Income in Q3 Despite Program Delays | PHGE Stock News - StockTitan
Atopic Dermatitis Drugs Market to Grow by USD 6.2 Billion (2024-2028), Driven by High Prevalence of the Condition, AI-Powered Report Explores Market EvolutionTechnavio - Yahoo Finance
BiomX (NYSEMKT:PHGE) Trading 4.6% Higher – Time to Buy? - Defense World
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024 - GlobeNewswire
Biomx stock plunges to 52-week low of $0.72 amid market challenges By Investing.com - Investing.com South Africa
Biomx stock plunges to 52-week low of $0.72 amid market challenges - Investing.com India
Biomx stock plunges to 52-week low, hits $0.87 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.87 By Investing.com - Investing.com South Africa
BiomX (NYSEMKT:PHGE) Trading Down 2.3%Here's Why - MarketBeat
BiomX announces a mandatory unit separation - MSN
BiomX announces mandatory unit separation - Yahoo Finance
BiomX Announces a Mandatory Unit Separation - The Manila Times
BiomX Inc (PHGE) Q2 2024 Earnings Call Highlights: Strong Financial Turnaround and Promising ... - Yahoo Finance
BiomX (NYSEAMERICAN:PHGE) Shares Down 1.5% – What’s Next? - Defense World
Biomx stock plunges to 52-week low, hitting $0.92 - Investing.com
Biomx stock plunges to 52-week low, hitting $0.92 By Investing.com - Investing.com South Africa
BiomX (NYSEMKT:PHGE) Stock Price Down 1% - Defense World
BiomX Shares Phage Therapy Advances and Vision - TipRanks
BiomX Inc Azioni (PHGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.95%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):